Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 1,173.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,401 shares of the company’s stock after purchasing an additional 3,134 shares during the period. Farther Finance Advisors LLC’s holdings in Twist Bioscience were worth $154,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC lifted its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. boosted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Emily M. Leproust sold 1,730 shares of Twist Bioscience stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the sale, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Robert F. Werner sold 1,448 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,356 shares of company stock valued at $3,205,239 over the last three months. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Down 0.3 %

Shares of Twist Bioscience stock opened at $45.40 on Monday. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. Twist Bioscience Co. has a twelve month low of $15.85 and a twelve month high of $60.90. The business’s 50 day simple moving average is $43.69 and its 200-day simple moving average is $45.74.

Analyst Ratings Changes

Several equities analysts have recently commented on TWST shares. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird upped their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Finally, Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.